Patents by Inventor Tomohiro Nakagaki
Tomohiro Nakagaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130041137Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val (SEQ ID NO: 1) as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val (SEQ ID NO: 2), and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.Type: ApplicationFiled: October 12, 2011Publication date: February 14, 2013Inventors: Kenji SOEJIMA, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Patent number: 8067221Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val (SEQ ID NO: 1) as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val (SEQ ID NO: 2), and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.Type: GrantFiled: April 16, 2008Date of Patent: November 29, 2011Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Publication number: 20100120693Abstract: A medicament for improving prognostic survival in therapy of malignant tumor is provided that may improve prognostic survival in DIC patients where the basal disease is malignant tumor, especially malignant tumor in hematopoietic organs. The medicament according to the invention comprises as a main active ingredient Activated Protein C, which is obtained from plasma or prepared by using the genetic recombination technique, and efficiently prolongs life-span of DIC patients where the basal disease is malignant tumor, especially malignant tumor in hematopoietic organs. In particular, the medicament may reduce adverse side effects of chemotherapeutics in chemotherapy of malignant tumor to enhance efficacy of said therapy and improve prognostic survival of patients suffering from malignant tumor.Type: ApplicationFiled: January 21, 2010Publication date: May 13, 2010Applicant: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Kenji OKAJIMA, Fujio Matsuo, Hiroyuki Sutoh, Yoichi Ogata, Tomohiro Nakagaki
-
Patent number: 7575872Abstract: It is intended to provide an antibody showing immunoreactivity selectively to ADAMTS-13 and applications of this antibody in epitope analysis or diagnosis of an ADAMTS-13 autoantibody-positive patient. Alternatively, it is intended to provide a process for producing and use of a modified ADAMTS-13 molecule partially deleted aiming at the application in pharmaceutical products. An antibody specific for ADAMTS-13 which can be obtained from a warm-blooded animal immunized and sensitized with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; a process for producing an antibody comprising a step of immunizing and sensitizing a warm-blooded animal with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; use of the above-described antibody including a method of detecting and purifying ADAMTS-13; and a modified ADAMTS-13 molecule partially deleted are provided.Type: GrantFiled: September 25, 2003Date of Patent: August 18, 2009Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Patent number: 7572591Abstract: The present invention provides an epitope recognized by an antibody (hereinafter, also referred to as an anti-ADAMTS-13 antibody) against a cleaving protease (hereinafter, also referred to as ADAMTS-13) specific to von Willebrand factor (hereinafter, also referred to as vWF), and a polypeptide comprising the epitope region. The present invention also provides a polypeptide located in a region from position 449 to position 687 in an amino acid sequence composing the ADAMTS-13, which is recognized by the anti-ADAMTS-13 antibody, or a peptide fragment derived from the polypeptide.Type: GrantFiled: March 17, 2004Date of Patent: August 11, 2009Assignee: The Juridical Foundation Chemo-Sero-Therapeutic Research InstituteInventors: Kenji Soejima, Tomohiro Nakagaki, Masanori Matsumoto, Yoshihiro Fujimura
-
Publication number: 20080254527Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val (SEQ ID NO: 1) as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val (SEQ ID NO: 2), and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.Type: ApplicationFiled: April 16, 2008Publication date: October 16, 2008Inventors: Kenji SOEJIMA, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Publication number: 20080182791Abstract: A medicament for improving prognostic survival in therapy of malignant tumor is provided that may improve prognostic survival in DIC patients where the basal disease is malignant tumor, especially malignant tumor in hematopoietic organs. The medicament according to the invention comprises as a main active ingredient Activated Protein C, which is obtained from plasma or prepared by using the genetic recombination technique, and efficiently prolongs life-span of DIC patients where the basal disease is malignant tumor, especially malignant tumor in hematopoietic organs. In particular, the medicament may reduce adverse side effects of chemotherapeutics in chemotherapy of malignant tumor to enhance efficacy of said therapy and improve prognostic survival of patients suffering from malignant tumor.Type: ApplicationFiled: February 22, 2008Publication date: July 31, 2008Applicant: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Kenji Okajima, Fujio Matsuo, Hiroyuki Sutoh, Yoichi Ogata, Tomohiro Nakagaki
-
Patent number: 7361748Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val (SEQ ID NO: 1) as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val (SEQ ID NO: 2), and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.Type: GrantFiled: December 8, 2005Date of Patent: April 22, 2008Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Patent number: 7329724Abstract: A novel hemostatic composition and a hemostatic pharmaceutical preparation are provided. A pharmaceutically stable hemostatic liquid composition comprising a mixed solution of activated blood coagulation factor VII (FVIIa) and blood coagulation factor X (FX) in a single container. The mixed solution is maintained at pH ranging from 5.0 to 6.5.Type: GrantFiled: July 10, 2002Date of Patent: February 12, 2008Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Tatsuya Araki, Kazuhiko Tomokiyo, Yasushi Nakatomi, Kaori Teshima, Tomohiro Nakagaki
-
Patent number: 7197554Abstract: A method of generating and linking programs required in a data linkage system to link data among a plurality of computer systems, for example a mainframe and an open system, is provided. In the data linkage system with a means for data transfer via a storage device, a program generation tool is prepared in the open system. The program generation tool reads a data stream definition and generates an intermediate file area securing program and a data linkage program A, both run on the mainframe, and a data linkage program B run on the open system. These programs are linked with one another. The intermediate file area securing program and the data linkage program A are transferred to the mainframe where they are executed.Type: GrantFiled: February 28, 2003Date of Patent: March 27, 2007Assignee: Hitachi, Ltd.Inventors: Yuichi Yagawa, Tomohiro Nakagaki, Toyohiro Nomoto, Hidehiko Ogasawara, Manabu Kitamura
-
Publication number: 20060251655Abstract: It is intended to provide an antibody showing immunoreactivity selectively to ADAMTS-13 and applications of this antibody in epitope analysis or diagnosis of an ADAMTS-13 autoantibody-positive patient. Alternatively, it is intended to provide a process for producing and use of a modified ADAMTS-13 molecule partially deleted aiming at the application in pharmaceutical products. An antibody specific for ADAMTS-13 which can be obtained from a warm-blooded animal immunized and sensitized with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; a process for producing an antibody comprising a step of immunizing and sensitizing a warm-blooded animal with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; use of the above-described antibody including a method of detecting and purifying ADAMTS-13; and a modified ADAMTS-13 molecule partially deleted are provided.Type: ApplicationFiled: September 25, 2003Publication date: November 9, 2006Inventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Publication number: 20060240476Abstract: The present invention provides an epitope recognized by an antibody (hereinafter, also referred to as an anti-ADAMTS-13 antibody) against a cleaving protease (hereinafter, also referred to as ADAMTS-13) specific to von Willebrand factor (hereinafter, also referred to as vWF), and a polypeptide comprising the epitope region. The present invention also provides a polypeptide located in a region from position 449 to position 687 in an amino acid sequence composing the ADAMTS-13, which is recognized by the anti-ADAMTS-13 antibody, or a peptide fragment derived from the polypeptide.Type: ApplicationFiled: March 17, 2004Publication date: October 26, 2006Inventors: Kenji Soejima, Tomohiro Nakagaki, Masanori Matsumoto
-
Patent number: 7112666Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val, and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.Type: GrantFiled: April 25, 2002Date of Patent: September 26, 2006Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Publication number: 20060094650Abstract: A medicament for improving prognostic survival in therapy of malignant tumor is provided that may improve prognostic survival in DIC patients where the basal disease is malignant tumor, especially malignant tumor in hematopoietic organs. The medicament according to the invention comprises as a main active ingredient Activated Protein C, which is obtained from plasma or prepared by using the genetic recombination technique, and efficiently prolongs life-span of DIC patients where the basal disease is malignant tumor, especially malignant tumor in hematopoietic organs. In particular, the medicament may reduce adverse side effects of chemotherapeutics in chemotherapy of malignant tumor to enhance efficacy of said therapy and improve prognostic survival of patients suffering from malignant tumor.Type: ApplicationFiled: December 26, 2003Publication date: May 4, 2006Applicant: Juridical Foundation the Chemo-Sero- Therapeutic Research InstituteInventors: Kenji Okajima, Fujio Matsuo, Hiroyuki Sutoh, Yoichi Ogata, Tomohiro Nakagaki
-
Patent number: 7033994Abstract: The present invention provides a pharmaceutical composition for treatment and prevention of bleeding disorders caused by platelet disorders, not caused by defect in blood coagulation factors or von Willebrand Factor but caused by reduction of circulating platelet count or platelet dysfunction, said composition comprising a hemostatic effective amount of Factor VIII and/or von Willebrand Factor. Also provided is a method for treating said bleeding, comprising administering a hemostatic effective amount of Factor VIII and/or von Willebrand Factor to patients suffering from bleeding disorders caused by platelet disorders.Type: GrantFiled: December 21, 2000Date of Patent: April 25, 2006Inventors: Tatsuya Araki, Kazuhiko Tomokiyo, Yasushi Nakatomi, Kaori Teshima, Tomoko Watanabe, Tomohiro Nakagaki
-
Publication number: 20060073569Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val (SEQ ID NO: 1) as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val (SEQ ID NO: 2), and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.Type: ApplicationFiled: December 8, 2005Publication date: April 6, 2006Inventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Patent number: 6881721Abstract: The present invention provides a pharmaceutical composition for treatment and prevention of hemorrhage associated with blood coagulation disorders, comprising activated Factor VII (FVIIa) and Factor X (FX) as an active ingredient. The pharmaceutical composition of the present invention contains no components causative side effects, is safe, highly efficacious, and easy to manage hemostasis. The pharmaceutical composition can be used for hemostatic management of patients suffering from hemorrhage associated with blood coagulation disorders, for example, disorders (including deficiency) of blood coagulation factors, especially caused by inhibitors (antibodies) against blood coagulation factors.Type: GrantFiled: December 21, 2000Date of Patent: April 19, 2005Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Yasushi Nakatomi, Kazuhiko Tomokiyo, Tatsuya Araki, Kaori Teshima, Tomoko Watanabe, Tomohiro Nakagaki
-
Publication number: 20040214275Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease.Type: ApplicationFiled: October 22, 2003Publication date: October 28, 2004Inventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Publication number: 20040147439Abstract: A novel hemostatic composition and a hemostatic pharmaceutical preparation are provided. A pharmaceutically stable hemostatic liquid composition comprising a mixed solution of activated blood coagulation factor VII (FVIIa) and blood coagulation factor X (FX) in a single container. The mixed solution is maintained at pH ranging from 5.0 to 6.5.Type: ApplicationFiled: January 12, 2004Publication date: July 29, 2004Inventors: Tatsuya Araki, Kazuhiko Tomokiyo, Yasushi Nakatomi, Kaori Teshima, Tomohiro Nakagaki
-
Publication number: 20030236849Abstract: A method of generating and linking programs required in a data linkage system to link data among a plurality of computer systems, for example a mainframe and an open system, is provided. In the data linkage system with a means for data transfer via a storage device, a program generation tool is prepared in the open system. The program generation tool reads a data stream definition and generates an intermediate file area securing program and a data linkage program A, both run on the mainframe, and a data linkage program B run on the open system. These programs are linked with one another. The intermediate file area securing program and the data linkage program A are transferred to the mainframe where they are executed.Type: ApplicationFiled: February 28, 2003Publication date: December 25, 2003Applicant: Hitachi, Ltd.Inventors: Yuichi Yagawa, Tomohiro Nakagaki, Toyohiro Nomoto, Hidehiko Ogasawara, Manabu Kitamura